ORAL PHARMACEUTICAL COMPOSITION

WIPO Patent Application WO/2021/029429

A1

Provided is a means that can prevent the initial excessive release of an active ingredient and sustainedly release said active ingredient in a therapeutically effective amount over a long period of time.

JP6262894	A therapeutic method of a central nervous system tumor
JP2018012710	CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
WO/2007/072911	PREPARATION WITH IMPROVED BIOABSORBABILITY OF SAPROPTERIN HYDROCHLORIDE

YOSHIMURA MOTOYASU (JP)
FUJII TAKUYA (JP)
KAMADA NAOKI (JP)
TOGASHI RYOHEI (JP)
AONO RYUTA (JP)
WANG XINYU (JP)

PCT/JP2020/030776

February 18, 2021

August 13, 2020

Click for automatic bibliography generation  

OTSUKA PHARMA CO LTD (JP)

A61K47/12; A61K31/496; A61K47/38

WO2013054872A1

2013-04-18

JP2014510023A	2014-04-24
JP2008115172A	2008-05-22
CN106667969A	2017-05-17
JP2006316052A	2006-11-24
US3173876A	1965-03-16
US3276586A	1966-10-04
US3541005A	1970-11-17
US3541006A	1970-11-17
US3546142A	1970-12-08
US3133132A	1964-05-12
US3865108A	1975-02-11
US4002173A	1977-01-11
US4207893A	1980-06-17
US2799241A	1957-07-16
US3916899A	1975-11-04
US4088864A	1978-05-09

FURUMOTO, KENTARO: "The close relationship with supersaturated formulation design and dissolution and precipitation mechanism", FARUMASHIA, vol. 47, no. 7, 30 November 2010 (2010-11-30), JP , pages 662 - 663, XP009533773, ISSN: 0014-8601, DOI: 10.14894/faruawpsj.47.7_662
HAWLEY MICHAEL, MOROZOWICH WALTER: "Modifying the diffusion layer of soluble salts of poorly soluble basic drugs to improve dissolution performance", MOLECULAR PHARMACEUTICS, vol. 7, no. 5, 2010, pages 1441 - 1449, XP055793460
See also references of EP 4015001A4

SAEGUSA & PARTNERS (JP)

View/Download PDF      PDF Help

Previous Patent: PRIVATE POWER GENERATION SYSTEM

Next Patent: ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND